INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 159 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2017. The put-call ratio across all filers is 0.64 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $9,230,000 | -17.5% | 116,000 | +16.0% | 1.26% | +23.7% |
| Q1 2019 | $11,186,000 | +208.0% | 100,000 | +233.3% | 1.02% | +65.5% |
| Q2 2017 | $3,632,000 | +114.0% | 30,000 | +100.0% | 0.62% | +85.8% |
| Q1 2017 | $1,697,000 | -41.5% | 15,000 | -14.3% | 0.33% | -10.3% |
| Q3 2015 | $2,903,000 | -31.3% | 17,500 | 0.0% | 0.37% | -10.6% |
| Q2 2015 | $4,224,000 | -0.1% | 17,500 | +16.7% | 0.41% | -5.9% |
| Q1 2015 | $4,230,000 | +171.2% | 15,000 | +50.0% | 0.44% | +65.4% |
| Q4 2014 | $1,560,000 | -54.7% | 10,000 | -31.3% | 0.27% | -37.6% |
| Q3 2014 | $3,447,000 | – | 14,565 | – | 0.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 234,375 | $23,623,000 | 22.67% |
| Boxer Capital, LLC | 600,000 | $60,474,000 | 7.47% |
| DLD Asset Management, LP | 834,600 | $84,136,000 | 5.77% |
| GREAT POINT PARTNERS LLC | 200,000 | $20,158,000 | 2.55% |
| BB BIOTECH AG | 575,719 | $58,027,000 | 1.86% |
| Elk Creek Partners, LLC | 207,657 | $20,930,000 | 1.74% |
| ALTRINSIC GLOBAL ADVISORS LLC | 277,944 | $28,014,000 | 1.34% |
| Sarissa Capital Management LP | 54,000 | $5,442,000 | 1.21% |
| QCM Cayman, Ltd. | 2,181 | $220,000 | 0.90% |
| Opus Point Partners Management, LLC | 3,534 | $356,000 | 0.78% |